Skip to main content
. 2022 Jan 28;19(3):106–110. doi: 10.1002/cld.1183

TABLE 2.

Novel Therapeutic Strategies to Reduce Visceral Adipose Tissue for Use in NAFLD

Novel Therapeutic Target Mechanism of action
Adiponectin replacement Increase fatty acid oxidation, reduce oxidative stress and liver fibrosis
Leptin replacement Promote lipid mobilization, reduce liver fat deposition
TZDs (PPAR‐γ agonist) Increase circulating adiponectin levels, regulate inflammation, improve fibrosis
SGLT‐2 inhibitor Reduce ectopic fat, reverse hepatic fibrosis